2026 жылында Израильде hifu-терапияға простата обырында бойынша ең жақсы бағалар мен клиникалар туралы біліңіз

HIFU in Israel achieves an 80% disease-free survival rate over 5 to 10 years for localized prostate cancer. Success metrics for low-risk groups reach 94.2% using advanced systems. Specialized centers like Sourasky Medical Center (Ichilov) utilize JCI-accredited protocols to ensure a 98% cancer-specific survival rate.

• Disease-free survival: Approximately 80% of patients remain disease-free 5 to 10 years after treatment.
• Cancer-specific survival: Long-term data shows a 98% survival rate specifically related to prostate cancer.
• Preservation of function: Low-risk profiles for incontinence and erectile dysfunction help maintain patient quality of life.
• Retreatment frequency: Around 20% of patients require a second session within 2 to 5 years.

Bookimed Expert Insight: Israeli clinics like Sourasky Medical Center often serve as high-volume hubs with over 1,800,000 patients annually. This volume allows surgeons like Professor Jack Baniel to master focal therapy techniques. His memberships in American and European urological associations ensure these success rates align with global standards.

Patient Consensus: Patients value how HIFU offers fewer side effects than surgery. Many view it as effective focal therapy but recognize that long-term monitoring of PSA levels is essential.

HIFU side effects for prostate cancer include temporary urinary frequency, urgency, and hematuria. Most patients experience mild burning for 1–2 weeks during recovery. While erectile dysfunction risk exists, it remains significantly lower than radical surgery, affecting approximately 5–20% of patients.

• Urinary retention: Temporary prostate swelling might require short-term catheter use.
• Sexual function: Many patients experience dry orgasms without impacting the sensation.
• Symptom management: Physicians often prescribe medications like Flomax to ease urination.
• Rare complications: Focal ablation significantly reduces risks of long-term urinary incontinence.

Bookimed Expert Insight: Israeli specialists like Professor Jack Baniel at Sourasky Medical Center often recommend partial gland ablation to preserve healthy tissue. Choosing focal therapy over full gland ablation can reduce side effect risks by nearly half while maintaining high oncological success. This approach is particularly effective for patients with localized tumors.

Patient Consensus: Many patients report that managing temporary urinary burning is easier than expected. Most emphasize that the trade-off for significantly lower erectile dysfunction risk makes this procedure their preferred choice.

HIFU is a fully authorized and legitimate medical procedure in Israel. The Israeli Ministry of Health approves its use for treating localized prostate cancer. Leading institutions like Sourasky Medical Center utilize advanced Focal One technology, focusing on nerve-preserving techniques to maintain quality of life.

• Regulatory status: Israel Ministry of Health approves HIFU for localized prostate cancer treatment.
• Leading facilities: JCI-accredited Sourasky Medical Center in Tel Aviv provides specialized urological oncology.
• Expert surgeons: Chief of Urology Jack Baniel performs HIFU and robotic prostatectomy procedures.
• Technology used: Clinics utilize advanced systems like Focal One and Sonablate 500 for therapy.

Bookimed Expert Insight: Israeli oncology centers demonstrate a unique trend by combining high-volume public hospital expertise with private-tier technology. Sourasky Medical Center treats 1,800,000 patients annually, meaning their urology teams manage complex cases that smaller international boutiques rarely see. This volume directly supports the high precision required for focal ultrasound therapy.

Patient Consensus: Patients prioritize HIFU for its ability to preserve erectile function compared to traditional surgery. Many emphasize confirming health fund coverage early, as focal therapy eligibility depends strictly on tumor Gleason scores.

Ideal candidates for HIFU are men with localized, low-to-intermediate risk prostate cancer who prioritize preserving sexual and urinary function. This non-surgical approach targets visible tumors via magnetic resonance imaging (MRI) and is most effective for small prostates with PSA levels below 20 ng/mL.

• Cancer stage: Disease must be localized (T1-T2) without spread to lymph nodes or bones.
• Gleason score: Most suitable for scores of 6 or low-volume Gleason 7 (3+4).
• Prostate volume: Optimal results occur when the prostate size is under 40-50 cc.
• Treatment history: Applicable as primary therapy or salvage treatment after failed radiation therapy.

Bookimed Expert Insight: Israel's leading centers, such as Sourasky Medical Center, treat 40,000 cancer patients annually. Data indicates that successful HIFU candidates often require high-quality MRI-fusion biopsies for precise mapping. Expert urologists like Professor Jack Baniel specialize in these nerve-preserving techniques to maintain life quality. This expertise is vital because focal therapy requires extreme precision to avoid re-treatment if the cancer is multifocal.

Patient Consensus: Patients value how this procedure maintains erectile and urinary function compared to radical surgery. Many suggest seeking a second opinion at a center of excellence specifically for focal therapy mapping.

Israeli specialists maintain high experience levels through advanced training and board certifications. Leading urologists at JCI-accredited centers like Sourasky Medical Center (Ichilov) often hold international fellowships at institutions such as Thomas Jefferson University and have authored over 100 scientific publications in oncological urology.

• Specialized fellowships: Experts complete rigorous training in Canada or the US for minimally invasive surgery.
• High surgical volume: Sourasky Medical Center performs 34,000 yearly operations with a 90% cancer success rate.
• Academic standing: Top doctors serve as Professors of Urology or Chairs of Radiation Oncology departments.
• Global recognition: Israeli clinics frequently rank among the Newsweek Top World Specialized Clinics for oncology.

Bookimed Expert Insight: Israeli specialists like Professor Jack Baniel often lead dedicated oncourological departments rather than general urology wards. This hyper-specialization is why centers like Sourasky handle 40,000 cancer patients annually. Patients benefit because their surgeon focuses exclusively on complex prostate cases using focal therapies like HIFU.

Patient Consensus: Many patients stress that the individual surgeon's specific volume of 100+ annual procedures is the most critical factor for success. They recommend prioritizing a specialist’s personal track record over a clinic’s general brand name.

High-intensity focused ultrasound (HIFU) is a non-invasive, radiation-free treatment that uses targeted sound waves to destroy localized prostate cancer. This focal therapy heats cancerous tissue to 190°F, causing cell death while preserving surrounding nerves, healthy muscle, and vital urinary and sexual functions.

• Treatment approach: Operates as a non-surgical lumpectomy using real-time MRI and ultrasound guidance.
• Functional preservation: Significantly lowers risks of urinary incontinence and erectile dysfunction versus surgery.
• Recovery timeline: Patients typically return to normal activities within 7 to 10 days.
• Post-operative care: Requires a urinary catheter for approximately 1 week to manage swelling.

Bookimed Expert Insight: Israel’s top centers, like Sourasky, integrate Newsweek-ranked oncology expertise with JCI-accredited safety. While HIFU prioritization preserves lifestyle, success depends on the operator. We recommend surgeons like Professor Jack Baniel, who combine HIFU with robotic surgery experience. This ensures the most appropriate treatment choice for localized versus aggressive staging.

Patient Consensus: Many patients choose this procedure to maintain their quality of life, accepting a higher trade-off for potential recurrence. They emphasize the necessity of frequent follow-up MRIs and choosing experienced operators to ensure tumor accessibility.

HIFU in Israel is a non-invasive, transrectal procedure that uses focused sound waves to heat and destroy localized prostate tumors. This technique targets diseased tissue at over 158°F while sparing surrounding erectile nerves. Experts at JCI-accredited centers like Sourasky Medical Center (Ichilov) perform this outpatient treatment in approximately 75 minutes.

• Targeting technology: Surgeons create 3D prostate models to pinpoint tumors using advanced imaging systems.
• Precise ablation: High-intensity ultrasound intersects at focal points to destroy tissue without any incisions.
• Anesthesia protocol: Patients undergo the procedure under general anesthesia or heavy sedation for comfort.
• Typical recovery: Most patients return home the same day but use a catheter for 10–14 days.

Bookimed Expert Insight: Israeli specialists like Professor Jack Baniel often combine HIFU with nerve-preserving techniques. This dual approach is why many patients choose Israel over other locations. Data shows Sourasky Medical Center manages over 40,000 cancer patients annually. This high volume ensures surgeons maintain the specialized skill required for precise ultrasound targeting.

Patient Consensus: Many patients find the lower risk of erectile dysfunction compared to surgery a major relief. Expect your PSA levels to spike briefly before dropping as the body clears the ablated tissue.